➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Medtronic
Moodys
Boehringer Ingelheim
Johnson and Johnson

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GS-9857


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for GS-9857?

GS-9857 is an investigational drug.

There have been 15 clinical trials for GS-9857. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2015.

The most common disease conditions in clinical trials are Hepatitis C, Infection, and Virus Diseases. The leading clinical trial sponsors are Gilead Sciences, University of Maryland, and Unity Health Care, Inc.

There are twenty-seven US patents protecting this investigational drug and seven hundred and one international patents.

Recent Clinical Trials for GS-9857
TitleSponsorPhase
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionGilead SciencesPhase 3
Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment StudyGilead SciencesPhase 3
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Subjects With Previous DAA ExperienceGilead SciencesPhase 2

See all GS-9857 clinical trials

Clinical Trial Summary for GS-9857

Top disease conditions for GS-9857
Top clinical trial sponsors for GS-9857

See all GS-9857 clinical trials

US Patents for GS-9857

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-9857   Start Trial Synthesis of an antiviral compound GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
GS-9857   Start Trial Combination formulation of two antiviral compounds Gilead Pharmasset LLC (Foster City, CA)   Start Trial
GS-9857   Start Trial Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
GS-9857   Start Trial Inhibitors of hepatitis C virus Gilead Pharmasset LLC (Foster City, CA)   Start Trial
GS-9857   Start Trial Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
GS-9857   Start Trial Nucleoside phosphoramidate prodrugs Pharmasset, Inc. (Princeton, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-9857

Drugname Country Document Number Estimated Expiration Related US Patent
GS-9857 Argentina 098959 2033-12-23   Start Trial
GS-9857 Australia 2014370125 2033-12-23   Start Trial
GS-9857 Canada 2934537 2033-12-23   Start Trial
GS-9857 China 105849118 2033-12-23   Start Trial
GS-9857 Eurasian Patent Organization 201691031 2033-12-23   Start Trial
GS-9857 European Patent Office 3087085 2033-12-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Colorcon
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.